Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Targeted Alpha-Particle Therapy for Hematologic Malignancies.

Jurcic JG.

J Med Imaging Radiat Sci. 2019 Jun 25. pii: S1939-8654(19)30276-0. doi: 10.1016/j.jmir.2019.05.008. [Epub ahead of print]

PMID:
31253514
2.

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes.

Ali AM, Huang Y, Pinheiro RF, Xue F, Hu J, Iverson N, Hoehn D, Coutinho D, Kayani J, Chernak B, Lane J, Hillyer C, Galili N, Jurcic J, Mohandas N, An X, Raza A.

Blood Adv. 2018 Jun 26;2(12):1393-1402. doi: 10.1182/bloodadvances.2018018440.

3.

Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.

Jurcic JG.

Curr Radiopharm. 2018;11(3):192-199. doi: 10.2174/1874471011666180525102814. Review.

PMID:
29793418
4.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

5.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
6.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

7.

Androgen Maintenance Therapy for Acute Myeloid Leukemia.

Jurcic JG.

J Clin Oncol. 2017 Feb;35(4):381-383. doi: 10.1200/JCO.2016.70.4999. Epub 2016 Nov 14. No abstract available.

PMID:
28129529
8.

Factors influencing pain therapy for metastatic cancer patients in Bosnia and Herzegovina.

Tica Sedlar I, Čale S, Parić A, Perić M, Jurčić J, Vrdoljak E.

Acta Med Acad. 2016 Nov;45(2):104-120. doi: 10.5644/ama2006-124.166.

9.

Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.

Jurcic JG.

JAMA Oncol. 2017 Mar 1;3(3):299-300. doi: 10.1001/jamaoncol.2016.3928. No abstract available.

PMID:
27787556
10.

Knowledge, Perceptions and Attitudes toward Chronic Pain and Its Management: A Cross-Sectional Survey of Frontline Pharmacists in Ontario, Canada.

Patel T, Chang F, Mohammed HT, Raman-Wilms L, Jurcic J, Khan A, Sproule B.

PLoS One. 2016 Jun 7;11(6):e0157151. doi: 10.1371/journal.pone.0157151. eCollection 2016.

11.

Severe mechanical hemolysis in a patient with thalassemia minor who had undergone inappropriate splenectomy.

Falchi L, Grillo LM, Diuguid-Gerber JL, Eisenberger AB, Jurcic JG.

Int J Hematol. 2016 Aug;104(2):147-8. doi: 10.1007/s12185-016-2023-1. Epub 2016 May 20. No abstract available.

PMID:
27206816
12.

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).

Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ.

Haematologica. 2016 Jun;101(6):781-8. doi: 10.3324/haematol.2015.140335. Epub 2016 Mar 4.

13.

Targeted alpha-particle immunotherapy for acute myeloid leukemia.

Jurcic JG, Rosenblat TL.

Am Soc Clin Oncol Educ Book. 2014:e126-31. doi: 10.14694/EdBook_AM.2014.34.e126. Review.

14.

FDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma.

Beylergil V, Simmons MZ, Ulaner G, Jurcic J, Hibshoosh H, Carrasquillo JA.

Clin Nucl Med. 2014 Mar;39(3):288-91. doi: 10.1097/RLU.0000000000000358.

PMID:
24458178
15.

Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram SL, Orsini JM Jr, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, Deblasio T, Jurcic JG, Nimer S, Peterson LC, Kwaan HC, Rowe JM, Douer D, Tallman MS.

Leuk Res. 2013 Sep;37(9):1004-9. doi: 10.1016/j.leukres.2013.05.007. Epub 2013 Jun 14.

PMID:
23768930
16.

Radioimmunotherapy for hematopoietic cell transplantation.

Jurcic JG.

Immunotherapy. 2013 Apr;5(4):383-94. doi: 10.2217/imt.13.11. Review.

PMID:
23557421
17.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

18.

Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.

Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, Douer D, Litzow MR, Lazarus HM, Rowe JM, Levine RL, Tallman MS.

Leuk Res. 2013 Jan;37(1):32-6. doi: 10.1016/j.leukres.2012.08.025. Epub 2012 Oct 24.

19.

T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.

Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MR, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Prockop SE, Yahalom J, Heller G, Perales MA.

Biol Blood Marrow Transplant. 2013 Feb;19(2):208-13. doi: 10.1016/j.bbmt.2012.09.003. Epub 2012 Sep 13.

20.

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.

Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG.

Haematologica. 2013 Jan;98(1):119-28. doi: 10.3324/haematol.2012.066613. Epub 2012 Jul 16.

21.

What happened to anti-CD33 therapy for acute myeloid leukemia?

Jurcic JG.

Curr Hematol Malig Rep. 2012 Mar;7(1):65-73. doi: 10.1007/s11899-011-0103-0. Review.

PMID:
22109628
22.

Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions.

Rosenblat TL, Jurcic JG.

Hematol Oncol Clin North Am. 2011 Dec;25(6):1189-213. doi: 10.1016/j.hoc.2011.09.007. Review.

PMID:
22093583
23.

Emerging new approaches for the treatment of acute promyelocytic leukemia.

Park J, Jurcic JG, Rosenblat T, Tallman MS.

Ther Adv Hematol. 2011 Oct;2(5):335-52. doi: 10.1177/2040620711410773.

24.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

25.

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS.

Blood. 2011 Aug 4;118(5):1248-54. doi: 10.1182/blood-2011-04-346437. Epub 2011 Jun 8.

26.

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG.

Clin Cancer Res. 2010 Nov 1;16(21):5303-11. doi: 10.1158/1078-0432.CCR-10-0382. Epub 2010 Sep 21.

27.

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA.

Blood. 2010 Jul 15;116(2):171-9. doi: 10.1182/blood-2009-10-250993. Epub 2010 Apr 16.

28.

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.

Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL.

Leuk Lymphoma. 2009 Aug;50(8):1336-44. doi: 10.1080/10428190903050013.

PMID:
19557623
29.

Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.

Harnicar S, Adel N, Jurcic J.

J Oncol Pharm Pract. 2009 Sep;15(3):175-82. doi: 10.1177/1078155208101959. Epub 2009 Mar 12.

PMID:
19282418
30.

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA.

J Clin Oncol. 2009 Feb 1;27(4):491-7. doi: 10.1200/JCO.2008.16.4459. Epub 2008 Dec 15.

31.

Ab therapy of AML: native anti-CD33 Ab and drug conjugates.

Jurcic JG.

Cytotherapy. 2008;10(1):7-12. Review.

PMID:
17917880
32.

St John's wort versus paroxetine for depression.

Jurcic J, Pereira JA, Kavanaugh D.

Can Fam Physician. 2007 Sep;53(9):1511-3. No abstract available.

33.

Diagnosis and treatment of acute promyelocytic leukemia.

Jurcic JG, Soignet SL, Maslak AP.

Curr Oncol Rep. 2007 Sep;9(5):337-44. Review.

PMID:
17706161
34.

Monoclonal antibody therapy of APL.

Maslak PG, Jurcic JG, Scheinberg DA.

Curr Top Microbiol Immunol. 2007;313:205-19. Review.

PMID:
17217045
35.

Antibody-drug conjugates in acute myeloid leukemia.

Scheinberg DA, Jurcic JG, Maslak P.

Nat Clin Pract Oncol. 2006 May;3(5):238-9. No abstract available.

PMID:
16682998
36.

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA.

J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6.

PMID:
16520464
37.

Immunotherapy for acute myeloid leukemia.

Jurcic JG.

Curr Oncol Rep. 2005 Sep;7(5):339-46. Review.

PMID:
16091194
38.

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D.

J Clin Oncol. 2005 Jun 20;23(18):4110-6.

PMID:
15961759
39.

The promise of targeted {alpha}-particle therapy.

Mulford DA, Scheinberg DA, Jurcic JG.

J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S. Review.

40.

Radioimmunotherapy of leukemia.

Burke JM, Jurcic JG.

Adv Pharmacol. 2004;51:185-208. Review. No abstract available.

PMID:
15464910
41.

Antibody-based treatment of acute myeloid leukaemia.

Mulford DA, Jurcic JG.

Expert Opin Biol Ther. 2004 Jan;4(1):95-105. Review.

PMID:
14680472
42.

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.

Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG.

Bone Marrow Transplant. 2003 Sep;32(6):549-56.

PMID:
12953125
43.

Monitoring PML-RARalpha in acute promyelocytic leukemia.

Jurcic JG.

Curr Oncol Rep. 2003 Sep;5(5):391-8. Review.

PMID:
12895391
44.

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D.

J Clin Oncol. 2003 Apr 1;21(7):1278-84.

PMID:
12663715
45.

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.

Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg D, Levitt D, Wedel N.

Leukemia. 2003 Feb;17(2):314-8.

PMID:
12592328
46.

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.

Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA.

Cancer. 2003 Feb 15;97(4):1025-32.

47.

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.

Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE.

Cancer. 2002 Aug 1;95(3):581-7.

48.

Impact of infection by vancomycin-resistant Enterococcus on survival and resource utilization for patients with leukemia.

Bach PB, Malak SF, Jurcic J, Gelfand SE, Eagan J, Little C, Sepkowitz KA.

Infect Control Hosp Epidemiol. 2002 Aug;23(8):471-4.

PMID:
12186216
49.

Targeted alpha particle immunotherapy for myeloid leukemia.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.

Blood. 2002 Aug 15;100(4):1233-9.

50.

Antibody therapy in acute myeloid leukemia: current status and future directions.

Burke JM, Jurcic JG.

Clin Lymphoma. 2002 Mar;2 Suppl 1:S12-8. Review.

PMID:
11970765

Supplemental Content

Loading ...
Support Center